Literature DB >> 21465658

Multiple increased osteoclast functions in individuals with neurofibromatosis type 1.

David A Stevenson1, Jincheng Yan, Yongzheng He, Huijie Li, Yaling Liu, Qi Zhang, Yongmin Jing, Zhiping Guo, Wei Zhang, Dalong Yang, Xiaohua Wu, Heather Hanson, Xiaohong Li, Karl Staser, David H Viskochil, John C Carey, Shi Chen, Lucy Miller, Kent Roberson, Laurie Moyer-Mileur, Menggang Yu, Elisabeth L Schwarz, Marzia Pasquali, Feng-Chun Yang.   

Abstract

Skeletal abnormalities including scoliosis, tibial dysplasia, sphenoid wing dysplasia, and decreased bone mineral density (BMD) are associated with neurofibromatosis type 1 (NF1). We report the cellular phenotype of NF1 human-derived osteoclasts and compare the in vitro findings with the clinical phenotype. Functional characteristics (e.g., osteoclast formation, migration, adhesion, resorptive capacity) and cellular mechanistic alterations (e.g., F-actin polymerization, MAPK phosphorylation, RhoGTPase activity) from osteoclasts cultured from peripheral blood of individuals with NF1 (N = 75) were assessed. Osteoclast formation was compared to phenotypic, radiologic, and biochemical data. NF1 osteoprogenitor cells demonstrated increased osteoclast forming capacity. Human NF1-derived osteoclasts demonstrated increased migration, adhesion, and in vitro bone resorption. These activities coincided with increased actin belt formation and hyperactivity in MAPK and RhoGTPase pathways. Although osteoclast formation was increased, no direct correlation of osteoclast formation with BMD, markers of bone resorption, or the clinical skeletal phenotype was observed suggesting that osteoclast formation in vitro cannot directly predict NF1 skeletal phenotypes. While NF1 haploinsufficiency produces a generalized osteoclast gain-in-function and may contribute to increased bone resorption, reduced BMD, and focal skeletal defects associated with NF1, additional and perhaps local modifiers are likely required for the development of skeletal abnormalities in NF1.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21465658      PMCID: PMC3080465          DOI: 10.1002/ajmg.a.33965

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  42 in total

1.  Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells.

Authors:  F C Yang; R Kapur; A J King; W Tao; C Kim; J Borneo; R Breese; M Marshall; M C Dinauer; D A Williams
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

2.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts.

Authors:  K P McHugh; K Hodivala-Dilke; M H Zheng; N Namba; J Lam; D Novack; X Feng; F P Ross; R O Hynes; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

3.  Neurofibromatosis type 1 growth charts.

Authors:  M Clementi; S Milani; I Mammi; S Boni; C Monciotti; R Tenconi
Journal:  Am J Med Genet       Date:  1999-12-03

4.  [Arterial complications of neurofibromatosis].

Authors:  J M Cormier; F Cormier; F Mayade; J M Fichelle
Journal:  J Mal Vasc       Date:  1999-10

5.  Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation.

Authors:  Eetu Heervä; Maria H Alanne; Sirkku Peltonen; Tommi Kuorilehto; Teuvo Hentunen; Kalervo Väänänen; Juha Peltonen
Journal:  Bone       Date:  2010-06-09       Impact factor: 4.398

6.  Renovascular disease and hypertension in children with neurofibromatosis.

Authors:  E Fossali; E Signorini; R C Intermite; E Casalini; A Lovaria; M M Maninetti; L N Rossi
Journal:  Pediatr Nephrol       Date:  2000-08       Impact factor: 3.714

7.  The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice.

Authors:  R P Atit; K Mitchell; L Nguyen; D Warshawsky; N Ratner
Journal:  J Invest Dermatol       Date:  2000-06       Impact factor: 8.551

8.  Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1.

Authors:  J L Rutkowski; K Wu; D H Gutmann; P J Boyer; E Legius
Journal:  Hum Mol Genet       Date:  2000-04-12       Impact factor: 6.150

9.  Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1).

Authors:  T Tucker; C Schnabel; M Hartmann; R E Friedrich; I Frieling; H-P Kruse; V-F Mautner; J M Friedman
Journal:  J Med Genet       Date:  2008-12-09       Impact factor: 6.318

10.  Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo.

Authors:  D A Ingram; F C Yang; J B Travers; M J Wenning; K Hiatt; S New; A Hood; K Shannon; D A Williams; D W Clapp
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

View more
  15 in total

1.  Valosin-containing protein and neurofibromin interact to regulate dendritic spine density.

Authors:  Hsiao-Fang Wang; Yu-Tzu Shih; Chiung-Ya Chen; Hsu-Wen Chao; Ming-Jen Lee; Yi-Ping Hsueh
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

2.  Partial Blindness to Submicron Topography in NF1 Haploinsufficient Cultured Fibroblasts Indicates a New Function of Neurofibromin in Regulation of Mechanosensoric.

Authors:  D Kaufmann; J Hoesch; Y Su; L Deeg; K Mellert; J P Spatz; R Kemkemer
Journal:  Mol Syndromol       Date:  2012-09-27

3.  Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.

Authors:  Aparna Kaul; Joseph A Toonen; Patrick J Cimino; Scott M Gianino; David H Gutmann
Journal:  Neuro Oncol       Date:  2014-12-21       Impact factor: 12.300

4.  Neurofibromatosis Type 1 With Cherubism-like Phenotype, Multiple Osteolytic Bone Lesions of Lower Extremities, and Alagille-syndrome: Case Report With Literature Survey.

Authors:  Reinhard E Friedrich; Jozef Zustin; Andreas M Luebke; Thorsten Rosenbaum; Martin Gosau; Christian Hagel; Felix K Kohlrusch; Ilse Wieland; Martin Zenker
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

5.  Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.

Authors:  Steven D Rhodes; Hao Yang; Ruizhi Dong; Keshav Menon; Yongzheng He; Zhaomin Li; Shi Chen; Karl W Staser; Li Jiang; Xiaohua Wu; Xianlin Yang; Xianghong Peng; Khalid S Mohammad; Theresa A Guise; Mingjiang Xu; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2015-05-21       Impact factor: 6.741

6.  Notching in the posterior border of the ramus of mandible in a patient with neurofibromatosis type I - a case report.

Authors:  Bhuvana Krishnamoorthy; Parul Singh; Suma N Gundareddy; Manisha Lakhanpal Sharma; Manu Dhillon
Journal:  J Clin Diagn Res       Date:  2013-10-05

7.  Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Authors:  Steven D Rhodes; Xiaohua Wu; Yongzheng He; Shi Chen; Hao Yang; Karl W Staser; Jiapeng Wang; Ping Zhang; Chang Jiang; Hiroki Yokota; Ruizhi Dong; Xianghong Peng; Xianlin Yang; Sreemala Murthy; Mohamad Azhar; Khalid S Mohammad; Mingjiang Xu; Theresa A Guise; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2013-12       Impact factor: 6.741

Review 8.  Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1.

Authors:  Steven D Rhodes; Feng-Chun Yang
Journal:  Curr Osteoporos Rep       Date:  2016-02       Impact factor: 5.096

9.  Hyperactive RAS/PI3-K/MAPK Signaling Cascade in Migration and Adhesion of Nf1 Haploinsufficient Mesenchymal Stem/Progenitor Cells.

Authors:  Yuan Zhou; Yongzheng He; Richa Sharma; Wen Xing; Selina A Estwick; Xiaohua Wu; Steven D Rhodes; Mingjiang Xu; Feng-Chun Yang
Journal:  Int J Mol Sci       Date:  2015-06-01       Impact factor: 5.923

10.  Neuronal excitation upregulates Tbr1, a high-confidence risk gene of autism, mediating Grin2b expression in the adult brain.

Authors:  Hsiu-Chun Chuang; Tzyy-Nan Huang; Yi-Ping Hsueh
Journal:  Front Cell Neurosci       Date:  2014-09-10       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.